Sign up
Pharma Capital

Edwards Lifesciences up on US$1bn stock repurchase programme, 2017 financial guidance

The company also said it had entered into a US$150mln accelerated stock buyback deal last month
1512654929_Heart-cells.jpg
"Our global growth is being driven by our transcatheter aortic valve therapies, and continued advancement in each of our market-leading product lines," said chief executive Michael A. Mussallem.

Edwards Lifesciences Corp (NYSE:EW) shares were up in premarket after announcing a new US$1bn stock repurchase programme and reaffirming its 2017 financial guidance.

In a statement, the heart disease treatment specialist, said it has authorised the new programme, which could represent about 4.2% of its outstanding shares.

Reaffirms 2017 guidance

Separately, the company said it had entered into a US$150mln accelerated stock buyback deal last month.

The life sciences company also reaffirmed the financial guidance it had given for 2017. It also projected 2018 adjusted earnings per share of US$4.10 to US$4.30.

Analysts are looking at a 2018 adjusted earnings per share of US$4.14.

Also in 2018, the company has guided revenue at US$3.5bn to US$3.9bn, representing an underlying growth of 9% to 10%.

The market consensus is for a 2018 revenue of US$3.7bn.

"Our global growth is being driven by our transcatheter aortic valve therapies, and continued advancement in each of our market-leading product lines," said chief executive Michael A. Mussallem.

In premarket trade, its shares were up 1.89% at US$115.50.



Register here to be notified of future EW Company articles
View full EW profile

Edwards Lifesciences Timeline

Newswire

Edwards Lifesciences tops S&P 500 gainers

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.